Galderma Group AGXSWX:GALD -0.14%15 Current Ratio is 1.19 as of Dec. 2025, which is at its 10-year median of 1.19. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 998 Drug Manufacturers companies, Galderma Group AG ranks worse than 76.35% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Galderma Group AG's current ratio for the quarter that ended in Dec. 2025 was 1.19.
Galderma Group AG has a current ratio of 1.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Galderma Group AG's Current Ratio or its related term are showing as below:
XSWX:GALD'
s Current Ratio Range Over the Past 10 Years
Min: 1.03 Med: 1.19 Max: 1.21
Current: 1.19
During the past 5 years, Galderma Group AG's highest Current Ratio was 1.21. The lowest was 1.03. And the median was 1.19.
XSWX:GALD's Current Ratio is ranked worse than 76.35% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs XSWX:GALD: 1.19
Galderma Group AG (XSWX:GALD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Galderma Group AG Current Ratio Related Terms
Galderma Group AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Current Ratio of 1.19 as of Dec. 2025. This is near median its historical median of 1.19. Over the past decade, Galderma Group AG's Current Ratio has ranged from 1.03 to 1.21. According to the industry distribution chart, Galderma Group AG ranks #762 out of 998 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Galderma Group AG's Current Ratio too high?
Galderma Group AG's current Current Ratio of 1.19 is near median its 10-year median of 1.19. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 1.21. The Drug Manufacturers industry median Current Ratio is 2.00. Galderma Group AG's value of 1.19 is 40.4% below this industry median. Based on the distribution chart, Galderma Group AG ranks #762 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #762 out of 998 companies for Current Ratio. This places Galderma Group AG in the lower half of its industry. The industry median Current Ratio is 2.00. Galderma Group AG's value of 1.19 is 40.4% below this benchmark. Historically, Galderma Group AG's own Current Ratio has ranged from 1.03 to 1.21 over the past decade. While the company's 10-year median is 1.19 vs. the industry median of 2.00, Galderma Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Current Ratio of 1.19 is 40.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Current Ratio is 1.19, which is near median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Current Ratio of 1.19. The current Current Ratio is 1.19, which is near median its 10-year median of 1.19 and 40.4% below the Drug Manufacturers industry median of 2.00. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Current Ratio is 1.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 